Beth F. Levine is General Counsel and CCO at KERYX BIOPHARMACEUTICALS INC (KERX). They have made 1 open-market trade across 1 company since 2007, most recently 2007-06-18.
CIK 0001397932
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $11K since 2007, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KERX | 1,000 | $3K |
Shares reported on the most recent Form 4, priced at the 2007-06-20 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KERX | BUY | 2007-06-18 | 2007-06-20 | $11.00 | $11K | -32.6% | -1.8% | -1.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.